Posters on the topic "Metabolism, Biochemistry & Drug Development"

Back
  • P003
The Role of Purine Auxotrophy in Toxoplasma-Host Interaction
  • Dr. Bruno Martorelli Di Genova (Burlington, VT / US)
  • P010
Anti-Apicomplexa drug discovery: Chemotherapeutic drug screening and target deconvolution in Toxoplasma gondii.
  • P012
Structural insight into the apicomplexan drug target cytochrome bc1
  • P014
Establishment of an E. coli model for studying the interaction and flexibility of apicoplast resident ferredoxin and bacterial flavodoxin redox systems towards IspH of the isoprenoid pathway
  • P015
Deciphering the transport of heme intermediates in Toxoplasma gondii: Insights from comparative genome wide CRISPR screens
  • P022
Cross linking mass spectrometry: A new tool for studies on the Toxoplasma gondii protein interactome
  • P026
Critical roles of an oxysterol-binding protein in lipid synthesis and trafficking in Toxoplasma gondii
  • P036
Activity and efficacy of the bumped kinase inhibitor BKI-1708 in vitro and in non-pregnant and pregnant toxoplasmosis and neosporosis mouse models
  • P038
TgGloL is an atypical glyoxalase domain-containing apicoplast protein that is important for the growth of Toxoplasma
  • P046
In vitro evaluation of natural compounds extracts from Tabebuia against Toxoplasma gondii proliferation
  • P047
Treatment with BKI-1748 after Toxoplasma gondii systemic dissemination in experimentally infected sheep significantly improves clinical outcome and prevents congenital infection
  • P056
Comparative proteomic analysis of Toxoplasma gondii Me49-derived strains adapted to in vitro treatments with thiosemicarbazones
  • P064
Innovative Assay Development and Targeted Screening Unveil Compounds Against Toxoplasma gondii Bradyzoite and Tachyzoite Forms
  • P068
Evaluation of the Trithiolato-Bridged Arene Ruthenium Complex Conjugated to 9-(2-hydroxyethyl)-Adenine (OD62-18) as a Potential Treatment for Toxoplasma gondii Infection.
  • P069
Commercial kitten moist food inactivated Toxoplasma gondii tissue cysts instantaneously
  • P074
MQ-1: A Promising Marinoquinoline Derivative Demonstrating Effectiveness in Treating Acute and Chronic Toxoplasmosis in Murine Models
  • P078
Elucidating the role of a mitochondrial superoxide dismutase in Toxoplasma gondii
  • P097
2,3-dihydro-1,4-benzodioxins are potent inhibitors of T. gondii tachyzoite regrowth in vitro
  • P099
Biochemical and Molecular Elucidation of Hydroquinine Mechanism(s) of Action against T. gondii
  • P101
RNA triphosphatase-mediated mRNA capping is essential for maintaining transcriptome homeostasis and the survival of Toxoplasma gondii
  • P104
Reinvention of the diagnostic algorithm and treatment options for reactivated toxoplasmosis – ToxoReTREAT project
  • P108
Searching for a vaccine against toxoplasmosis
  • P112
Compounds From the MMV Pathogen Box Target Toxoplasma gondii Tachyzoites and Bradyzoites: Insights into Metabolic Responses and the Role of the bc1-Complex in Bradyzoites
  • P114
The myxobacterial compound Argyrin D inhibits protein translation in the mitochondria of Toxoplasma gondii and arrests tachyzoites and bradyzoites.
  • P116
Differential Gene Expression of Toxoplasma gondii ME49 and RH Strains during ELQ-316 Inhibition
  • P121
In Vitro Activity of Fractionated Methanoic Blueberry Extract against Toxoplasma gondii growth
    • v1.19.0
    • © Conventus Congressmanagement & Marketing GmbH